How Much Do You Get Paid for Donating a Kidney?

In the United States and most countries worldwide, you get paid nothing for donating a kidney. The National Organ Transplant Act of 1984 (NOTA) makes it a federal crime to receive “valuable consideration” for an organ, punishable by up to five years in prison or a $50,000 fine. Far from profiting, most living kidney donors actually lose money. Research tracking donor finances has found that roughly nine out of ten donors end up with a net financial loss in the year following surgery, with about a third losing more than $2,500.

Why Selling a Kidney Is Illegal

NOTA was enacted in 1984 to prevent a commercial market in human organs. Congress was concerned that allowing organ sales would exploit the poor and undermine public trust in the transplant system. The law bans buying or selling any human organ for transplantation, and it has withstood legal challenges. In 2011, the U.S. Court of Appeals for the Ninth Circuit upheld the law’s constitutionality, though it carved out a narrow exception for peripheral blood stem cells obtained through a specific collection method.¹ That ruling did not change anything for solid organs like kidneys. If someone offers you money for a kidney, the transaction itself is illegal for both parties.

The prohibition extends beyond cash. “Valuable consideration” is interpreted broadly to cover most forms of compensation. There are exceptions for reasonable expenses related to travel, housing, and lost wages, but those are framed as reimbursement, not payment. The distinction matters legally and ethically: the system is designed so that donors are not supposed to profit, but ideally shouldn’t go broke either. In practice, that second goal often falls short.

What Donors Actually Spend

The recipient’s insurance or Medicare typically covers the donor’s surgical costs, including the hospital stay, the operation itself, and related medical tests. But a long list of expenses falls outside that coverage. A prospective study of living kidney donors found that most incurred direct costs like ground transportation, meals, medications, lodging, and sometimes airfare. The median direct cost was around $433, but the range stretched from as little as $6 to over $10,000. More than a third of donors reported lost wages in the first year, with a median wage loss of about $2,700.²

A separate prospective study put the median out-of-pocket costs at about $1,250, with a quarter of donors exceeding $5,500 in combined out-of-pocket and lost productivity costs.³ Another study looking specifically at the breakdown found that donors collectively missed over 33,000 work hours, 40% of which were unpaid, resulting in roughly $300,000 in total lost wages across the cohort. About 89% of donors ended up with a net financial loss.⁴

These numbers don’t capture the full picture for every donor. Recovery time varies. Some people are back at a desk job within two to three weeks; others doing physical labor need six weeks or more. If your job doesn’t offer paid medical leave, those weeks off can hit hard. Caregivers who help donors during recovery also lose wages, adding another layer of cost the studies track but donors rarely anticipate.

Programs That Help With Costs

The federal government does fund a program called the National Living Donor Assistance Center (NLDAC), which reimburses travel, lodging, meals, lost wages, and dependent care for donors who qualify based on financial need. The program was established with a grant from the Health Resources and Services Administration and is managed by a transplant professional society.⁵ NLDAC can make a meaningful difference for donors who know about it and qualify, but it is means-tested and doesn’t cover everyone.

Transplant centers sometimes have their own donor assistance funds, and some recipients or their families cover donor expenses directly. But even among donors who received a local or national grant, over half still reported moderate to severe financial burden. Many donors also dipped into savings, borrowed from friends or family, took out loans, or organized fundraisers to cover their costs.⁶ The gap between what assistance programs provide and what donation actually costs is a persistent problem in the transplant world.

Crowdfunding and Its Complications

GoFundMe campaigns and similar platforms have become a common way for both recipients and donors to cover transplant-related expenses. But crowdfunding in this space raises ethical and legal questions that most people don’t think about when they share a donation link. A content analysis of newspaper coverage found that about 10% of articles about transplant crowdfunding mentioned at least one ethical or policy concern, including possible violations of federal laws prohibiting “valuable consideration” for organs, complications around taxing funds raised, loss of Medicaid or disability benefits for recipients, and questions about accountability for how money gets used.⁷

The legal line can get blurry. Reimbursing a donor for documented travel and lodging is permitted. But a crowdfunding campaign that raises a large, unspecified sum for a donor could look like compensation rather than expense reimbursement, and the difference is legally significant. The transplant community has not fully resolved how to handle this, and most donors and recipients launching fundraisers don’t consult a lawyer first.

State Laws on Donor Leave and Tax Benefits

Many U.S. states have tried to ease the financial burden through legislation offering paid leave for organ donors or tax deductions and credits for donation-related expenses. The idea is straightforward: if lost wages are the biggest financial barrier, guarantee donors paid time off. If out-of-pocket costs deter potential donors, offer a tax break. On paper, these policies seem like they should work.

The evidence, though, is discouraging. One study that analyzed cross-state variation in donor leave and tax legislation found no significant impact on the quantity of organs donated. The laws did boost bone marrow donations, which makes sense because bone marrow donation is less invasive, involves a shorter recovery, and means the guaranteed leave actually covers most of the disruption. For kidney donation, which requires major surgery and weeks of recovery, the incentives appear too small relative to the burden.⁸ A separate analysis of state policies reached a similar conclusion, finding that paid leave, tax incentives, and other state-level measures had no robust association with donation rates or transplant numbers.⁹

This doesn’t mean these laws are useless. They help individual donors who benefit from them. But the evidence suggests they are not enough, on their own, to move the needle on the national kidney shortage.

Insurance Problems After Donation

One financial risk donors rarely hear about before surgery is what happens with insurance afterward. Federal legislation like the Living Donor Protection Act has been introduced to address this, specifically aiming to prohibit life, disability, and long-term care insurance companies from discriminating against living donors.¹⁰ But protections remain incomplete, and donors have reported real difficulties.

A study of donors who changed or initiated health insurance after donation found that about 7% reported difficulty, with some denied coverage altogether and others charged higher premiums or told they had a preexisting condition because of the donation. The picture was worse for life insurance: a quarter of donors who changed or initiated life insurance afterward encountered problems, including outright denial and higher premiums.¹¹ A broader systematic review found that while most insurance companies said they would cover donors with no premium increase, somewhere between 3% and 11% of donors actually ran into problems. In one study within the review, donors whose premiums went up were less likely to say they’d donate again.¹²

Health insurance under the Affordable Care Act offers more protection, since marketplace plans cannot deny coverage or charge more for preexisting conditions. But life insurance, disability insurance, and long-term care insurance operate under different rules, and the gap in protection is real. If you’re considering donation, it’s worth checking your insurance situation beforehand, especially for policies outside the ACA framework.

The Long-Term Health Risk That Could Become a Financial Risk

Kidney donation is generally safe, and most donors live normal, healthy lives with one kidney. But the long-term data shows a measurable increase in the risk of developing end-stage kidney disease yourself. A Norwegian study followed over 1,900 donors for a median of about 25 years and found an eleven-fold higher risk of end-stage kidney disease compared to healthy non-donors. A much larger U.S. study of over 96,000 donors found an eight-fold increase, with the risk at 15 years after donation reaching about 31 per 10,000 donors compared to roughly 4 per 10,000 among comparable non-donors.¹³

The relative increase sounds alarming, but the absolute risk remains low. Thirty-one out of every 10,000 donors means the vast majority will never need dialysis or a transplant. Still, for the small percentage who do develop kidney problems decades later, the financial consequences can be severe. Dialysis is extraordinarily expensive, and if insurance gaps exist because of the donation history, the donor could face a situation that is both medically and financially devastating. This is one reason advocates push so hard for comprehensive insurance protections for donors.

Why the Healthcare System Saves Money on Every Transplant

There’s an irony at the core of this issue. While donors often lose money, the healthcare system saves enormous amounts whenever a kidney transplant happens instead of keeping someone on dialysis. A Swedish study estimated that while transplantation costs more in the first year, it saves roughly €36,000 to €45,000 per patient in each of the following two years.¹⁴ Across 14 European countries, the average annual net savings from transplantation over dialysis were about $37,500 per patient, with the transplant paying for itself within about three years on average.¹⁵

U.S. data is even more striking. One real-world comparison found that over 24 months, preemptive kidney transplant cost about $304,000 per patient, while maintenance dialysis cost about $637,000, a difference of roughly $333,000 per person.¹⁶ The system saves hundreds of thousands of dollars per transplant, yet the person who makes it possible by donating a kidney absorbs thousands of dollars in unreimbursed costs. This disconnect is a central argument in the growing push for policy change.

The Debate Over Compensating Donors

A growing number of researchers and ethicists have argued that some form of regulated compensation could increase the supply of living kidneys and reduce the shortage. One economic analysis estimated that to encourage enough donations to address the current waitlist, the government would need to compensate living donors approximately $77,000 per person.¹⁷ Given that each transplant saves the system hundreds of thousands of dollars compared to dialysis, the math works out favorably from a pure cost-benefit standpoint.

Proposals for regulated compensation emphasize that they are not the same as an open market. Researchers have outlined models using existing infrastructure, where compensation would be standardized and administered through the transplant system rather than negotiated between buyer and seller.¹⁸ Trials of such systems have been proposed to test whether they increase donation rates and whether incentivized donors have the same medical and psychological outcomes as those who donate purely for altruistic reasons.¹⁹

On the other side, critics worry that paying for kidneys would inevitably exploit vulnerable people. Research on kidney markets in countries where organs are bought and sold, including unregulated markets in parts of South Asia and the regulated system in Iran, has documented significant physical, psychological, social, and financial harms to sellers. A review of this literature argued that such harms would likely persist even under a regulated system.²⁰ Evidence from India’s kidney market, for example, suggests that selling a kidney rarely improves the seller’s long-term financial situation in a meaningful way.²¹

Others push back on the exploitation argument. Some ethicists contend that the charge of “commodification” has not been specific enough to justify the ban, that donors should not be forced to act on purely altruistic motives when lives are at stake, and that compensation could actually reduce the exploitation that already exists in current organ procurement by bringing transactions into a transparent, regulated framework.²² Australia has implemented a compensation scheme that some ethicists argue is sufficiently well designed to avoid these pitfalls by reimbursing donors generously without creating a price-driven market.²³

Non-Monetary Incentives and Voucher Programs

While the compensation debate remains unresolved, some creative alternatives have emerged. Kidney voucher programs allow someone to donate a kidney now and receive a voucher guaranteeing that a designated person, often a family member, will receive a kidney in the future if needed. The voucher isn’t money, so it doesn’t run afoul of NOTA. It gives the donor something of real value: peace of mind that their loved one will be taken care of. These programs operate within paired kidney exchange networks, where a donor whose blood type or tissue doesn’t match their intended recipient can donate to a stranger while their recipient gets a compatible kidney from someone else’s donor.²⁴

The concept is appealing, but operationally complex. A voucher issued today might not be redeemed for a decade or more, and the transplant center that issued it may not be the same center that eventually performs the transplant. Questions about portability, liability, and what happens if the program changes or the issuing center closes remain only partially answered. Still, voucher donation represents one of the few ways to offer donors a tangible benefit without crossing the legal line into organ sales.

The Push Toward Financial Neutrality

Rather than full compensation, many transplant professionals now advocate for “financial neutrality,” the idea that donation should cost the donor exactly nothing. Not a windfall, not a loss, just zero net impact. This would mean comprehensive reimbursement for every documented expense, including lost wages at actual salary levels, travel, childcare, lodging, and any post-donation medical care related to the surgery. Advocates frame this as a necessary step to increase living donation rates and reduce the kidney shortage.²⁵

Financial neutrality sounds like a moderate, common-sense position, and it largely is. But achieving it in practice requires substantial policy infrastructure: expanding the NLDAC, mandating donor leave at the federal level, protecting donors from insurance discrimination, and ensuring that reimbursement programs are accessible and well-publicized. The gap between the principle and the reality is wide, and until it narrows, the typical living kidney donor will continue to pay, not be paid, for one of the most generous acts a person can perform.